China approves HCV drugs from Gilead and AbbVie

By Chris Lieu | Sep 29, 2017 | 9:31 PM GMT

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir (GS-7977) to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen

Read the full 240 word article

How to gain access

Continue reading with a
two-week free trial.